Evidence map›Paper›PMID 19528989›Full record

ArticleKidney international2009

Circulating TGF-beta1 as a reliable biomarker for chronic kidney disease progression in the African-American population.

Soo Bong Lee, Keizo Kanasaki, Raghu Kalluri

Open access · bronzeAbstract readComment
In one paragraph

Article in Kidney international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. A functionalClinical kidney journal · 2022
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Role of TGF-β in a mouse model of high turnover renal osteodystrophy.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2014
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Soo Bong LeeDivision of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
Keizo Kanasaki
Raghu Kalluri
Beth Israel Deaconess Medical Center · US

Funding

TYPE IV COLLAGEN IN ALPORT SYNDROME PATHOGENESISR01DK055001 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 1999 to 2014
$4.3M
Regulation of Angiogenesis by TumstatinR01DK062987 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KALLURI, RAGHU · 2003 to 2006
$1.4M
Matrix Microenvironment and Liver FibrosisR01AA013913 · NIAAA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KALLURI, RAGHU · 2005 to 2007
$994k
The Biology and Function of BMP-7 in the KidneyR01DK061688 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KALLURI, RAGHU · 2005 to 2007
$746k
NIAAA NIH HHS R01 AA013913NIDDK NIH HHS DK13193NIDDK NIH HHS DK55001NIDDK NIH HHS DK61688NIDDK NIH HHS DK62987NIDDK NIH HHS R01 DK055001NIDDK NIH HHS R01 DK061688NIDDK NIH HHS R01 DK062987
6 · The paper itself

Abstract

Progressive renal fibrosis is common to all chronic kidney diseases (CKD). Suthanthiran and colleagues identified a positive association between transforming growth factor-beta1 and several risk factors for CKD progression in African Americans but not in whites. This study offers a possible explanation for the higher prevalence of end-stage renal disease in African Americans and highlights the need for a better therapeutic strategy for this population.

Indexed as

BiomarkersBlack or African AmericanDisease ProgressionHumansKidney Failure, ChronicModels, BiologicalPopulation GroupsPrevalenceRisk FactorsTransforming Growth Factor beta1United StatesBiomarkersTGFB1 protein, humanTransforming Growth Factor beta1

Identifiers

PMID19528989
PMCPMC4313549
OpenAlexW2043729075

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.